Private prison operator CoreCivic (NYSE: CXW) reported Q3 2026 results topping the market’s revenue expectations, with sales up 28.2% year on year to $744.1 million. Its non-GAAP profit of $0.49 per share was 14% above analysts’ consensus estimates.

Is now the time to buy CXW? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

CoreCivic delivered higher-than-expected revenue and earnings in the latest quarter, yet the market responded negatively, likely reflecting concerns raised on the earnings call about contract modifications, leadership changes, and the impact of recent asset sales. CEO Lucibeth Mayberry cited increased occupancy rates and heightened enforcement activity by government partners as key drivers, noting, “Federal partners, primarily ICE and the U.S. Marshals Service, comprised 53% of CoreCivic’s total revenue in the third quarter.” The company also emphasized the significance of its Clinical Solutions Pharmacy acquisition and strong demand from ICE as important contributors. However, management acknowledged that some of the positive momentum could be offset in coming quarters by modifications to existing management contracts at facilities recently sold to the federal government.

Looking ahead, management raised its annual adjusted EPS and EBITDA guidance, driven by expectations of stable residential populations, continued demand from ICE, and incremental contributions from newly activated facilities. CFO David Garfinkle highlighted ongoing capital allocation priorities, including share repurchases and investments in operational technology. Mayberry stated, “We believe this funding framework positions ICE to sustain detention capacity at or near current contracted levels for the foreseeable future.” While the company signals confidence in its strategic direction, it flagged that future government policy shifts and potential changes to contract terms could create uncertainty for the business.

Key insights from management’s remarks

Management attributed the quarter’s performance to stronger occupancy, new government contracts, and portfolio optimization via asset sales, while also addressing executive transition and capital allocation priorities.

• ICE demand and facility activation: CoreCivic benefitted from a substantial increase in ICE detainee populations, with recently activated contracts at facilities such as California City and Diamondback helping to lift occupancy rates to post-pandemic highs. These new contracts contributed meaningfully to segment profitability but were still ramping toward full margin contribution.
• Asset sales bolster balance sheet: The sale of four facilities to the Department of Homeland Security generated $1.6 billion in after-tax net proceeds, allowing CoreCivic to repay over $700 million in debt and execute a sizable accelerated share repurchase program. Management stressed that these transactions provide both financial flexibility and highlight the underlying value of the company’s real estate portfolio.
• Leadership transition: The resignation of CEO Patrick Swindle for health reasons led to Lucibeth Mayberry’s appointment as Chief Executive Officer. The transition was acknowledged as unexpected, but management emphasized continuity in strategic priorities and highlighted Swindle’s ongoing role as special advisor.
• Clinical Solutions Pharmacy acquisition: The April acquisition of Clinical Solutions Pharmacy expanded CoreCivic’s services segment, adding $82.8 million in quarterly revenue and improving segment margins. Management sees this business as a platform for future growth and a way to better serve government partners’ pharmacy needs.
• Share repurchase focus: Leveraging the proceeds from asset sales, CoreCivic accelerated its share buyback activity, resulting in a 13.8% reduction in weighted average shares outstanding. The board further increased the buyback authorization, signaling ongoing commitment to capital returns.

Drivers of future performance

Management’s updated outlook is anchored by stable demand from federal partners, further facility activations, and ongoing capital deployment, but acknowledges uncertainties related to government policy and contract terms.

• Stable ICE and federal demand: Management expects continued high utilization of CoreCivic’s detention facilities by ICE, citing multi-year funding frameworks that provide visibility through 2029. CEO Lucibeth Mayberry noted the absence of signals suggesting reduced demand and emphasized, “They have secure funding to do so, and that goes through 2029.”
• Operational leverage from new contracts: Additional ramp-up of newly activated facilities is anticipated to drive incremental earnings, especially as locations like Appleton reach full operational status in the coming year. However, some margin pressure may persist until these facilities are fully utilized.
• Potential contract modifications and asset sales: Management flagged that modifications to management contracts at recently sold facilities could reduce per-bed payments, impacting future margins. Preliminary discussions with ICE on further asset sales add another layer of uncertainty, as timing and terms remain unknown.

Catalysts in upcoming quarters

Looking forward, StockStory analysts will watch (1) the pace and financial impact of management contract modifications at facilities sold to the federal government, (2) the continued ramp-up and profitability of newly activated contracts and facilities, and (3) any developments around further asset sales to ICE. The execution of share repurchase plans and success of the Clinical Solutions Pharmacy integration will also be key markers for tracking CoreCivic’s strategy.

CoreCivic currently trades at $28.93, down from $30.52 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.